RxSight (RXST) Income from Continuing Operations (2020 - 2026)
RxSight's (RXST) quarterly Income from Continuing Operations came in at 15884000.0 in Q1 2026, down 93.94% YoY from 262278145.16 in Q1 2025, and down 73.56% on a QoQ basis from 9152000.0 in Q4 2025.
RxSight (RXST) Income from Continuing Operations (2020 - 2026) Analysis & Trends
RxSight (RXST) has 7 years of Income from Continuing Operations data on file, last reported at 15884000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 93.94% year-over-year to 15884000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46638000.0 (down 76.31% YoY) and the FY2025 annual result came in at 38944000.0, down 42.32% from the prior year.
- Income from Continuing Operations eased to 15884000.0 in Q1 2026, from 9152000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 53507000.0 in Q4 2022 to a low of 17596000.0 in Q1 2022.
- A 5-year average of 4095588.24 and a median of 9816000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 440.07% in 2022, down 158.57% in 2022.
- Tracing RXST's Income from Continuing Operations over 5 years: stood at 53507000.0 in 2022, then retreated by 7.23% to 49636000.0 in 2023, then slumped by 111.78% to 5846000.0 in 2024, then sank by 56.55% to 9152000.0 in 2025, then sank by 73.56% to 15884000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 15884000.0 (Q1 2026), 9152000.0 (Q4 2025), and 9816000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 201.00 Mn |
| 10 | RxSight | 251.23 Mn | -153.02 Mn | - | -12.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.10 Mn |
| Mar 31, 2026 | -15.88 Mn |
| Dec 31, 2025 | -9.15 Mn |
| Sep 30, 2025 | -9.82 Mn |
| Jun 30, 2025 | -11.79 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -5.85 Mn |
| Sep 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -6.08 Mn |
| Mar 31, 2024 | -9.10 Mn |
| Dec 31, 2023 | 49.64 Mn |
| Sep 30, 2023 | -12.42 Mn |
| Jun 30, 2023 | -13.80 Mn |
| Mar 31, 2023 | -13.21 Mn |
| Dec 31, 2022 | 53.51 Mn |
| Sep 30, 2022 | -16.82 Mn |
| Jun 30, 2022 | -16.73 Mn |
| Mar 31, 2022 | -17.60 Mn |
| Dec 31, 2021 | -15.73 Mn |
| Sep 30, 2021 | -12.67 Mn |